The COVID-19 antibody treatment developed by partners GlaxoSmithKline PLC and Vir Biotechnology Inc. has initially been found effective against the Omicron variant, the companies announced in a WSJ report.
- The two firms said their drug sotrovimab was tested against individual mutations found in the Omicron variant, and preliminary results found that the treatment was effective but has yet to be peer-reviewed.
- The drug targets a spot on the spike protein also found in other variants of the coronavirus, which is thought to have less likelihood of mutation. The preliminary results come as it was tested against mutations seen in other variants.
- The Omicron variant contains at least two mutations that overlap with the target site of the sotrovimab drug, according to Glaxo COVID-19 Monoclonal Antibody Development Lead Amanda Peppercorn.
The drug has already scored approval in about a dozen countries including the United States which has paid almost a billion dollars for doses. GSK is up 0.73%, while VIR is down 0.36%.